# Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Study · id `cardio:ct-nct05103332` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05103332](<https://clinicaltrials.gov/study/NCT05103332>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05103332

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 663 participants.

## Technical summary

Registry record NCT05103332. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2023-12-11 (actual). Results posted on 2025-07-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 663 participants (enrolled count; ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Started: 2021-11-05 (actual) (ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Primary completion: 2023-12-11 (actual) (ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Completion: 2024-09-13 (actual) (ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Results first posted: 2025-07-09 (ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Countries: United States; Canada; Estonia; Germany; Latvia; Lithuania; Poland; United Kingdom (ClinicalTrials.gov record NCT05103332, source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05103332-2025-11-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
- Acronym: KARDIA-2
- Condition: Hypertension
- Intervention (Drug): Indapamide
- Intervention (Drug): Amlodipine
- Intervention (Drug): Olmesartan
- Intervention (Drug): Placebo
- Intervention (Drug): Zilebesiran
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Indapamide (`cardio:indapamide`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry intervention name matches this record: Olmesartan (`cardio:olmesartan`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial (`cardio:pubmed-40434761`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 965cfd22b090846859889288f9b130e69c32eac919ee3bd49a0c698a64de46d2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
